ContraFect

ContraFect Inventory

Inventory of ContraFect (CFRXQ) as of Oct 19, 2026.

Inventory

-USD

Last updated:

Inventory of ContraFect is 2026 - USD. Inventory of ContraFect was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of Inventory ContraFect since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ContraFect

All Key Metrics — ContraFect